SCHEMBL13337073

SCHEMBL13337073

Cc1coc(-c2ccn3ccnc3c2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3C3 Q8NEB9 1/20 0.38
PIK3CD O00329 2/20 0.37
ABL1 P00519 2/20 0.37
EGFR P00533 2/20 0.37
HCK P08631 2/20 0.37
SRC P12931 2/20 0.37
PIK3CA P42336 2/20 0.37
PIK3CB P42338 2/20 0.37
MTOR P42345 2/20 0.37
PIK3CG P48736 2/20 0.37
EPHB4 P54760 2/20 0.37
PRKDC P78527 2/20 0.37
KDR P35968 1/20 0.37
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
PTPN11 Q06124 1/20 0.35
TGFBR1 P36897 5/20 0.34
AOC3 Q16853 2/20 0.34
DYRK1A Q13627 2/20 0.33
HDAC4 P56524 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3185826 0.76 PIK3C3 (0.45) PIK3C3PIK3CDABL1EGFRHCK
SCHEMBL16588373 0.75 FLT3 (0.40) KDRDDB1CRBNTGFBR1AOC3
SCHEMBL10175031 0.75 FGFR3 (0.42) PIK3C3PIK3CDABL1EGFRHCK
SCHEMBL13337071 0.73 FLT3 (0.38) KDRDDB1CRBNTGFBR1AOC3
SCHEMBL17275734 0.73 DDB1 (0.47) DDB1CRBNAOC3DYRK1A
SCHEMBL3196822 0.72 TGFBR1 (0.54) PIK3C3PIK3CDABL1EGFRHCK
SCHEMBL14826051 0.71 PIK3C3 (0.51) PIK3C3PIK3CDABL1EGFRHCK
SCHEMBL13680619 0.71 CYP3A4 (0.44) PIK3C3PIK3CDABL1EGFRHCK
SCHEMBL13680570 0.70 PIK3C3 (0.39) PIK3C3PIK3CDABL1EGFRHCK
SCHEMBL11925504 0.70 PIK3C3 (0.39) PIK3C3PIK3CDABL1EGFRHCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2114941-B1 BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS ASTEX THERAPEUTICS LTD (GB) 2015-03-25 EP disclosed
US-8895745-B2 Bicyclic heterocyclic compounds as FGFR inhibitors ASTEX THERAPEUTICS LIMITED (GB) 2014-11-25 US disclosed
US-8895745-B2 Bicyclic heterocyclic compounds as FGFR inhibitors ASTEX THERAPEUTICS LIMITED (GB) 2014-11-25 US disclosed
US-20100120761-A1 Bicyclic Heterocyclic Compounds as FGFR Inhibitors ASTEX THERAPEUTICS LIMITED (GB) 2010-05-13 US disclosed
US-20100120761-A1 Bicyclic Heterocyclic Compounds as FGFR Inhibitors ASTEX THERAPEUTICS LIMITED (GB) 2010-05-13 US disclosed
WO-2008078091-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120761-A1 Bicyclic Heterocyclic Compounds as FGFR Inhibitors FGFR3, FGFR1, FGFR2 PIK3C3 1137/4885PIK3CD 261/4885ABL1 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.